A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

NCT05714202 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1135

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: TAR-200
BIOLOGICAL: Cetrelimab
BIOLOGICAL: BCG Vesiculture

Sponsor

Janssen Research & Development, LLC